SEC Form 4

FORM 4

1. Name and Address of Reporting Person*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). \Box

KAZIMI A J

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS</u>

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									

		hours per response: 0.5							
	_								
	tionship of Re all applicable		Perso	n(s) to Issuer					
Х	Director		Х	10% Owner					
Х	Officer (give below)	e title		Other (specif below)	у				
	Chai	irman a	nd C	EO					

(Last) 2525 WEST EI SUITE 950	(First)	(Middle)	INC 3. Dat	[CPIX] e of Earliest Transa					2 X X	Director Officer (give title below) Chairman	X 10% C Other below and CEO	(specify
(Street) NASHVILLE	TN (State)	37203 (Zip)	4. If A	mendment, Date of	f Origina	l Filec	I (Month/Day/	6. Indi Line) X	- /			
		Table I - Nor	n-Derivative S	ecurities Acq	uired,	Dis	posed of,	or Ber	eficially	/ Owned		
1. Title of Security	1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Execution Date,		ction Instr.				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock			04/16/2021		Р		15(1)	Α	\$3.03	5,767,734	D	
Common Stock			04/19/2021		Р		15(1)	A	\$3.04	5,767,749	D	
Common Stock			04/20/2021		Р		15(1)	A	\$3.02	5,767,764	D	
Common Stock			04/21/2021		Р		15(1)	A	\$2.97	5,767,779	D	
				1	1	1	1	1	i	1	1	1

Common Stock	04/19/2021	Р	15(1)	A	\$3.04	5,767,749	D	
Common Stock	04/20/2021	Р	15(1)	A	\$3.02	5,767,764	D	
Common Stock	04/21/2021	Р	15(1)	A	\$2.97	5,767,779	D	
Common Stock	04/22/2021	Р	15(1)	A	\$2.96	5,767,794	D	
Common Stock	04/23/2021	Р	15(1)	A	\$2.99	5,767,809	D	
Common Stock	04/26/2021	Р	15(1)	A	\$2.97	5,767,824	D	
Common Stock	04/27/2021	Р	15(1)	A	\$2.94	5,767,839	D	
Common Stock	04/28/2021	Р	15 ⁽¹⁾	A	\$2.94	5,767,854	D	
Common Stock	04/29/2021	Р	15 ⁽¹⁾	A	\$2.89	5,767,869	D	
Common Stock	04/30/2021	Р	15 ⁽¹⁾	A	\$2.78	5,767,884	D	
Common Stock	05/03/2021	Р	15 ⁽¹⁾	A	\$2.66	5,767,899	D	
Common Stock	05/04/2021	Р	15 ⁽¹⁾	A	\$2.66	5,767,914	D	
Common Stock	05/05/2021	Р	15 ⁽¹⁾	A	\$2.73	5,767,929	D	
Common Stock	05/06/2021	Р	15 ⁽¹⁾	A	\$2.74	5,767,944	D	
Common Stock	05/07/2021	Р	15 ⁽¹⁾	A	\$2.73	5,767,959	D	
Common Stock	05/10/2021	Р	15 ⁽¹⁾	A	\$2.71	5,767,974	D	
Common Stock	05/11/2021	Р	15(1)	A	\$2.68	5,767,989	D	
Common Stock	05/12/2021	Р	15(1)	A	\$2.86	5,768,004	D	
Common Stock	05/13/2021	Р	15(1)	A	\$2.88	5,768,019	D	
Common Stock	05/14/2021	Р	15(1)	A	\$2.81	5,768,034	D	
Common Stock	05/17/2021	Р	15(1)	A	\$2.84	5,768,049	D	
Common Stock	05/18/2021	Р	15(1)	A	\$2.89	5,768,064	D	
Common Stock	05/19/2021	Р	15 ⁽¹⁾	A	\$2.83	5,768,079	D	
Common Stock	05/20/2021	Р	15 ⁽¹⁾	A	\$2.94	5,768,094	D	
Common Stock	05/21/2021	Р	15 ⁽¹⁾	A	\$3.06	5,768,109	D	
Common Stock	05/24/2021	Р	15 ⁽¹⁾	A	\$3.05	5,768,124	D	
Common Stock	05/25/2021	Р	15(1)	A	\$2.91	5,768,139	D	
Common Stock	05/26/2021	Р	15(1)	A	\$2.85	5,768,154	D	
Common Stock	05/27/2021	Р	15(1)	A	\$2.94	5,768,169	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of E		Expiration Date (Month/Day/Year)			e and Int of rities rlying ative rity (Instr. 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.

Remarks:

A.J. Kazimi by /s/ John Hamm 09/10/2021

<u>as attorney-in-fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.